TY - STD TI - Ostrom QT, de Blank PM, Kruchko C, Petersen CM, Liao P, Finlay JL et al (2015) Alex's lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-Oncology. https://doi.org/10.1093/neuonc/nou327 ID - ref1 ER - TY - STD TI - Pui C-H, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS (2011) Challenging issues in pediatric oncology. Nat Rev Clin Oncol. https://doi.org/10.1038/nrclinonc.2011.95 ID - ref2 ER - TY - STD TI - Gajjar A, Pfister SM, Taylor MD, Gilbertson RJ (2014) Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-14-0833 ID - ref3 ER - TY - STD TI - Heffron TP (2018) Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels. Neuro-Oncology. https://doi.org/10.1093/neuonc/nox179 ID - ref4 ER - TY - STD TI - Liu K-W, Pajtler KW, Worst BC, Pfister SM, Wechsler-Reya RJ (2017) Molecular mechanisms and therapeutic targets in pediatric brain tumors. Sci Signal. https://doi.org/10.1126/scisignal.aaf7593 ID - ref5 ER - TY - STD TI - Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC et al (2018) BRAF inhibition in BRAFV600-mutant Gliomas: results from the VE-BASKET study. J Clin Oncol. https://doi.org/10.1200/JCO.2018.78.9990 ID - ref6 ER - TY - STD TI - Gambella A, Senetta R, Collemi G, Vallero SG, Monticelli M, Cofano F et al (2020) NTRK fusions in central nervous system Tumors: A Rare, but Worthy Target. Int J Mol Sci. https://doi.org/10.3390/ijms21030753 ID - ref7 ER - TY - STD TI - Daneman R, Prat A (2015) The blood-brain barrier. CSH Perspect Biol. https://doi.org/10.1101/cshperspect.a020412 ID - ref8 ER - TY - STD TI - Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF (2011) Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med. https://doi.org/10.1017/S1462399411001888 ID - ref9 ER - TY - JOUR AU - Cordon-Cardo, C. AU - O'Brien, J. P. AU - Casals, D. AU - Rittman-Grauer, L. AU - Biedler, J. L. AU - Melamed, M. R. PY - 1989 DA - 1989// TI - Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites JO - Proc Natl Acad Sci U S A VL - 86 UR - https://doi.org/10.1073/pnas.86.2.695 DO - 10.1073/pnas.86.2.695 ID - Cordon-Cardo1989 ER - TY - STD TI - Eisenblätter T, Galla H-J (2002) A new multidrug resistance protein at the blood–brain barrier. Biochem Bioph Res Co. https://doi.org/10.1016/S0006-291X(02)00376-5 ID - ref11 ER - TY - STD TI - Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT et al (2016) Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell. https://doi.org/10.1016/j.ccell.2016.03.002 ID - ref12 ER - TY - STD TI - Camidge DR, Bang Y-J, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(12)70344-3 ID - ref13 ER - TY - STD TI - Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA et al (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-10-1564 ID - ref14 ER - TY - STD TI - Sledge GW (2010) Heading in a new direction: drug permeability in breast cancer brain metastasis. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-10-2502 ID - ref15 ER - TY - STD TI - Swain SM, Baselga J, Miles D, Im Y-H, Quah C, Lee LF et al (2014) Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. https://doi.org/10.1093/annonc/mdu133 ID - ref16 ER - TY - STD TI - Rankovic Z (2015) CNS drug design: balancing physicochemical properties for optimal brain exposure. J Med Chem. https://doi.org/10.1021/jm501535r ID - ref17 ER - TY - STD TI - Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD et al (2005) In vitro models for the blood-brain barrier. Toxicol in Vitro. https://doi.org/10.1016/j.tiv.2004.06.011 ID - ref18 ER - TY - STD TI - Pajouhesh H, Lenz GR (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx. https://doi.org/10.1602/neurorx.2.4.541 ID - ref19 ER - TY - STD TI - Fong CW (2015) Permeability of the blood-brain barrier: molecular mechanism of transport of drugs and physiologically important compounds. J Membrane Biol. https://doi.org/10.1007/s00232-015-9778-9 ID - ref20 ER - TY - STD TI - Guntner AS, Thalhamer B, Klampfl C, Buchberger W (2019) Collision cross sections obtained with ion mobility mass spectrometry as new descriptor to predict blood-brain barrier permeation by drugs. Sci Rep. https://doi.org/10.1038/s41598-019-55856-7 ID - ref21 ER - TY - STD TI - Nau R, Sörgel F, Eiffert H (2010) Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. https://doi.org/10.1128/CMR.00007-10 ID - ref22 ER - TY - STD TI - Ghersi-Egea J-F, Strazielle N (2001) Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus. Microsc Res Techniq. https://doi.org/10.1002/1097-0029(20010101)52:1<83:AID-JEMT10>3.0.CO;2-N ID - ref23 ER - TY - STD TI - Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis. https://doi.org/10.1016/j.nbd.2009.07.030 ID - ref24 ER - TY - STD TI - Scheife RT (2017) Protein Binding: What Does it Mean? DICP Ann Pharmac. https://doi.org/10.1177/106002808902300706 ID - ref25 ER - TY - STD TI - Buzanovskii VA (2017) Determination of proteins in blood. Part 1: determination of total protein and albumin. Rev J Chem. https://doi.org/10.1134/S2079978017010010 ID - ref26 ER - TY - STD TI - Smith DA, Di L, Kerns EH (2010) The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. https://doi.org/10.1038/nrd3287 ID - ref27 ER - TY - STD TI - Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D et al (2011) Protein binding: do we ever learn? Antimicrob Agents Ch. https://doi.org/10.1128/AAC.01433-10 ID - ref28 ER - TY - STD TI - Guntner AS, Stöcklegger S, Kneidinger M, Illievich U, Buchberger W (2019) Development of a highly sensitive gas chromatography-mass spectrometry method preceded by solid-phase microextraction for the analysis of propofol in low-volume cerebral microdialysate samples. J Sep Sci. https://doi.org/10.1002/jssc.201801066 ID - ref29 ER - TY - STD TI - Musteata FM, Pawliszyn J, Qian MG, Wu J-T, Miwa GT (2006) Determination of drug plasma protein binding by solid phase microextraction. J Pharm Sci. https://doi.org/10.1002/jps.20558 ID - ref30 ER - TY - STD TI - Wong M, Schlaggar BL, Buller RS, Storch GA, Landt M (2000) Cerebrospinal fluid protein concentration in pediatric patients. Arch Pediat Adol Med. https://doi.org/10.1001/archpedi.154.8.827 ID - ref31 ER - TY - STD TI - Lin J (2008) CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab. https://doi.org/10.2174/138920008783331077 ID - ref32 ER - TY - STD TI - Nagaya Y, Nozaki Y, Kobayashi K, Takenaka O, Nakatani Y, Kusano K et al (2014) Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates. Drug Metab Pharmacokinet. https://doi.org/10.2133/dmpk.DMPK-14-RG-026 ID - ref33 ER - TY - STD TI - Di L, Rong H, Feng B (2013) Demystifying brain penetration in central nervous system drug discovery. Miniperspective J Med Chem. https://doi.org/10.1021/jm301297f ID - ref34 ER - TY - STD TI - Warren KE (2018) Beyond the blood:brain barrier: the importance of central nervous system (CNS) pharmacokinetics for the treatment of CNS tumors, Including Diffuse Intrinsic Pontine Glioma. Front Oncol. https://doi.org/10.3389/fonc.2018.00239 ID - ref35 ER - TY - STD TI - Peyrl A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech T et al (2012) Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.24006 ID - ref36 ER - TY - STD TI - Ramalingam SS, Parise RA, Ramanathan RK, Ramananthan RK, Lagattuta TF, Musguire LA et al (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-07-0162 ID - ref37 ER - TY - STD TI - Clive S, Woo MM, Nydam T, Kelly L, Squier M, Kagan M (2012) Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-012-1940-9 ID - ref38 ER - TY - STD TI - Rydberg P, Gloriam DE, Olsen L (2010) The SMARTCyp cytochrome P450 metabolism prediction server. Bioinformatics. https://doi.org/10.1093/bioinformatics/btq584 ID - ref39 ER - TY - STD TI - Rydberg P, Gloriam DE, Zaretzki J, Breneman C, Olsen L (2010) SMARTCyp: a 2D method for prediction of cytochrome P450-mediated drug metabolism. ACS Med Chem Lett. https://doi.org/10.1021/ml100016x ID - ref40 ER - TY - STD TI - Rydberg P, Olsen L (2012) Ligand-based site of metabolism prediction for cytochrome P450 2D6. ACS Med Chem Lett. https://doi.org/10.1021/ml200246f ID - ref41 ER - TY - STD TI - Rydberg P, Olsen L (2012) Predicting drug metabolism by cytochrome P450 2C9: comparison with the 2D6 and 3A4 isoforms. ChemMedChem. https://doi.org/10.1002/cmdc.201200160 ID - ref42 ER - TY - STD TI - Rydberg P, Rostkowski M, Gloriam DE, Olsen L (2013) The contribution of atom accessibility to site of metabolism models for cytochromes P450. Mol Pharm. https://doi.org/10.1021/mp3005116 ID - ref43 ER - TY - STD TI - Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. https://doi.org/10.1038/srep42717 ID - ref44 ER - TY - STD TI - Englinger B, Lötsch D, Pirker C, Mohr T, van Schoonhoven S, Boidol B et al (2016) Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-a receptor-activated ABCB1 expression. Oncotarget. https://doi.org/10.18632/oncotarget.10324 ID - ref45 ER - TY - STD TI - Avery LB, Sacktor N, McArthur JC, Hendrix CW (2013) Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration. Antimicrob Agents Ch. https://doi.org/10.1128/AAC.02329-12 ID - ref46 ER - TY - STD TI - Dallinger C, Trommeshauser D, Marzin K, Liesener A, Kaiser R, Stopfer P (2016) Pharmacokinetic properties of Nintedanib in healthy volunteers and patients with advanced Cancer. J Clin Pharmacol. https://doi.org/10.1002/jcph.752 ID - ref47 ER - TY - STD TI - Rasmussen TA, Tolstrup M, Møller HJ, Brinkmann CR, Olesen R, Erikstrup C et al (2015) Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system. Open Forum Infect Dis. https://doi.org/10.1093/ofid/ofv037 ID - ref48 ER - TY - STD TI - Zopf D, Fichtner I, Bhargava A, Steinke W, Thierauch K-H, Diefenbach K et al (2016) Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. Cancer Med. https://doi.org/10.1002/cam4.883 ID - ref49 ER - TY - STD TI - Liu L, Detering J-C, Milde T, Haefeli WE, Witt O, Burhenne J (2014) Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood. J Chromatogr B. https://doi.org/10.1016/j.jchromb.2014.02.014 ID - ref50 ER - TY - STD TI - Rashid U, Hassan SF, Nazir S, Wadood A, Waseem M, Ansari FL (2015) Synthesis, docking studies, and in silico ADMET predictions of some new derivatives of pyrimidine as potential KSP inhibitors. Med Chem Res. https://doi.org/10.1007/s00044-014-1120-z ID - ref51 ER - TY - STD TI - de Lange ECM (2013) Utility of CSF in translational neuroscience. J Pharmacokinet Pharmacodyn. https://doi.org/10.1007/s10928-013-9301-9 ID - ref52 ER - TY - STD TI - Peyrl A, Chocholous M, Azizi AA, Czech T, Dorfer C, Mitteregger D et al (2014) Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. J Neuro-Oncol. https://doi.org/10.1007/s11060-014-1531-1 ID - ref53 ER - TY - JOUR AU - Goldberg, J. M. AU - Glade-Bender, J. AU - Sulis, M. L. AU - Gardner, R. A. AU - Pollard, J. A. AU - Aquino, V. AU - Winick, N. J. PY - 2014 DA - 2014// TI - A phase I dose finding study of Panobinostat in children with hematologic malignancies: initial report of TACL study T2009-012 in children with acute leukemia JO - Blood VL - 124 UR - https://doi.org/10.1182/blood.V124.21.3705.3705 DO - 10.1182/blood.V124.21.3705.3705 ID - Goldberg2014 ER - TY - STD TI - Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ et al (2008) Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. https://doi.org/10.1124/dmd.107.018267 ID - ref55 ER - TY - STD TI - Zhang Y, Qiang S, Yu Z, Zhang W, Xu Z, Yang L et al (2014) LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma. J Chromatogr Sci. https://doi.org/10.1093/chromsci/bmt037 ID - ref56 ER - TY - STD TI - Hellmann MD, Sturm I, Trnkova ZJ, Lettieri J, Diefenbach K, Rizvi NA et al (2015) Preliminary safety, pharmacokinetics, and efficacy of Regorafenib, Cisplatin, and Pemetrexed in patients with advanced nonsquamous non-small-cell lung cancers. Clin Lung Cancer. https://doi.org/10.1016/j.cllc.2015.04.003 ID - ref57 ER - TY - BOOK AU - Samant, T. S. AU - Dhuria, S. AU - Lu, Y. AU - Laisney, M. AU - Yang, S. AU - Grandeury, A. PY - 2018 DA - 2018// TI - Ribociclib bioavailability is not affected by gastric pH changes or food PB - In Silico and Clinical Evaluations. Clin Pharmacol Ther CY - Intake UR - https://doi.org/10.1002/cpt.940 DO - 10.1002/cpt.940 ID - Samant2018 ER - TY - STD TI - Parise RA, Holleran JL, Beumer JH, Ramalingam S, Egorin MJ (2006) A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum. J Chromatogr B. https://doi.org/10.1016/j.jchromb.2006.04.044 ID - ref59 ER - TY - STD TI - Pardridge WM (2011) Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS. https://doi.org/10.1186/2045-8118-8-7 ID - ref60 ER - TY - STD TI - Chen Y, Agarwal S, Shaik NM, Chen C, Yang Z, Elmquist WF (2009) P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther. https://doi.org/10.1124/jpet.109.154781 ID - ref61 ER - TY - STD TI - Mittapalli RK, Chung AH, Parrish KE, Crabtree D, Halvorson KG, Hu G et al (2016) ABCG2 and ABCB1 limit the efficacy of Dasatinib in a PDGF-B-driven brainstem Glioma model. Mol Cancer Ther. https://doi.org/10.1158/1535-7163.MCT-15-0093 ID - ref62 ER - TY - STD TI - Patel YT, Davis A, Baker SJ, Campagne O, Stewart CF (2019) CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-019-03864-9 ID - ref63 ER - TY - STD TI - Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A et al (2019) Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma. J Neuro-Oncol. https://doi.org/10.1007/s11060-019-03258-0 ID - ref64 ER - TY - STD TI - Tien A-C, Li J, Bao X, Derogatis A, Kim S, Mehta S et al (2019) A phase 0 trial of Ribociclib in recurrent Glioblastoma patients incorporating a tumor Pharmacodynamic- and pharmacokinetic-guided expansion cohort. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-0133 ID - ref65 ER - TY - STD TI - Porkka K, Koskenvesa P, Lundán T, Rimpiläinen J, Mustjoki S, Smykla R et al (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. https://doi.org/10.1182/blood-2008-02-140665 ID - ref66 ER - TY - STD TI - Koschmann C, Zamler D, MacKay A, Robinson D, Wu Y-M, Doherty R et al (2016) Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget. https://doi.org/10.18632/oncotarget.11602 ID - ref67 ER - TY - STD TI - Osorio DS, Finlay JL, Dhall G, Goldman S, Eisenstat D, Brown RJ (2013) Feasibility of dasatinib in children and adolescents with new or recurrent central nervous system germinoma. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.24567 ID - ref68 ER - TY - STD TI - Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S-I (2002) Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol. https://doi.org/10.1046/j.1365-2141.2002.03881.x ID - ref69 ER - TY - STD TI - Lombardi G, de Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M et al (2019) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30675-2 ID - ref70 ER - TY - STD TI - Daudigeos-Dubus E, Le Dret L, Lanvers-Kaminsky C, Bawa O, Opolon P, Vievard A et al (2015) Regorafenib: antitumor activity upon mono and combination therapy in preclinical pediatric malignancy models. PLoS One. https://doi.org/10.1371/journal.pone.0142612 ID - ref71 ER - TY - STD TI - Milde T, Lodrini M, Savelyeva L, Korshunov A, Kool M, Brueckner LM et al (2012) HD-MB03 is a novel group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. J Neuro-Oncol. https://doi.org/10.1007/s11060-012-0978-1 ID - ref72 ER - TY - STD TI - Gschwind H-P, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P et al (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos. https://doi.org/10.1124/dmd.105.004283 ID - ref73 ER - TY - STD TI - Zangardi ML, Spring LM, Blouin GC, Bardia A (2017) Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Expert Rev Clin Pharmacol. https://doi.org/10.1080/17512433.2017.1376653 ID - ref74 ER -